These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37300381)

  • 21. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
    Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
    Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
    Vazquez-Lombardi R; Loetsch C; Zinkl D; Jackson J; Schofield P; Deenick EK; King C; Phan TG; Webster KE; Sprent J; Christ D
    Nat Commun; 2017 May; 8():15373. PubMed ID: 28497796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells.
    Heuser C; Guhlke S; Matthies A; Bender H; Barth S; Diehl V; Abken H; Hombach A
    Int J Cancer; 2004 Jun; 110(3):386-94. PubMed ID: 15095304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulating antibody-dependent cellular cytotoxicity of epidermal growth factor receptor-specific heavy-chain antibodies through hinge engineering.
    D'Eall C; Pon RA; Rossotti MA; Krahn N; Spearman M; Callaghan D; van Faassen H; Hussack G; Stetefeld J; Butler M; Durocher Y; Zhang J; Henry KA; Tanha J
    Immunol Cell Biol; 2019 Jul; 97(6):526-537. PubMed ID: 30680791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody Conjugations via Glycosyl Remodeling.
    Toftevall H; Nyhlén H; Olsson F; Sjögren J
    Methods Mol Biol; 2020; 2078():131-145. PubMed ID: 31643054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of B-cell lymphoma with chimeric IgG and single-chain Fv antibody-interleukin-2 fusion proteins.
    Liu SJ; Sher YP; Ting CC; Liao KW; Yu CP; Tao MH
    Blood; 1998 Sep; 92(6):2103-12. PubMed ID: 9731068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photoconjugation of an Fc-Specific Peptide Enables Efficient DAR 2 Antibody-Drug Conjugate Formation.
    Lee T; Kim JH; Kwon SJ; Park SH; Kim J; Kang HJ; Chung SJ
    Org Lett; 2020 Nov; 22(21):8419-8423. PubMed ID: 33074682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
    Rataj F; Jacobi SJ; Stoiber S; Asang F; Ogonek J; Tokarew N; Cadilha BL; van Puijenbroek E; Heise C; Duewell P; Endres S; Klein C; Kobold S
    Br J Cancer; 2019 Jan; 120(1):79-87. PubMed ID: 30429531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marked enhancement of antigen-specific T-cell responses by IL-7-fused nonlytic, but not lytic, Fc as a genetic adjuvant.
    Nam HJ; Song MY; Choi DH; Yang SH; Jin HT; Sung YC
    Eur J Immunol; 2010 Feb; 40(2):351-8. PubMed ID: 19950168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD25 monoclonal antibody Fc variants differentially impact regulatory T cells and immune homeostasis.
    Huss DJ; Pellerin AF; Collette BP; Kannan AK; Peng L; Datta A; Wipke BT; Fontenot JD
    Immunology; 2016 Jul; 148(3):276-86. PubMed ID: 27012310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy.
    Kujawski M; Li L; Bhattacharya S; Wong P; Lee WH; Williams L; Li H; Chea J; Poku K; Bowles N; Vaidehi N; Yazaki P; Shively JE
    BMC Cancer; 2019 Sep; 19(1):882. PubMed ID: 31488104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetically Encoded Azide Containing Amino Acid in Mammalian Cells Enables Site-Specific Antibody-Drug Conjugates Using Click Cycloaddition Chemistry.
    VanBrunt MP; Shanebeck K; Caldwell Z; Johnson J; Thompson P; Martin T; Dong H; Li G; Xu H; D'Hooge F; Masterson L; Bariola P; Tiberghien A; Ezeadi E; Williams DG; Hartley JA; Howard PW; Grabstein KH; Bowen MA; Marelli M
    Bioconjug Chem; 2015 Nov; 26(11):2249-60. PubMed ID: 26332743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.
    Liu Y; Wang Y; Xing J; Li Y; Liu J; Wang Z
    Drug Des Devel Ther; 2018; 12():2645-2654. PubMed ID: 30214153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Baculovirus expression of a functional single-chain immunoglobulin and its IL-2 fusion protein.
    Bei R; Schlom J; Kashmiri SV
    J Immunol Methods; 1995 Oct; 186(2):245-55. PubMed ID: 7594624
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
    Zhang D; Goldberg MV; Chiu ML
    J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A recombinant anti-erbB2, scFv-Fc-IL-2 fusion protein retains antigen specificity and cytokine function.
    Shi M; Xie Z; Feng J; Sun Y; Yu M; Shen B; Guo N
    Biotechnol Lett; 2003 May; 25(10):815-9. PubMed ID: 12882013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
    MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.